Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Cybin Inc. (HELP)
Company Research
Source: GlobeNewswire
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLCProven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system (“CNS”) programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this year This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (“Helus”) (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds
Show less
Read more
Impact Snapshot
Event Time:
HELP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HELP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HELP alerts
High impacting Cybin Inc. news events
Weekly update
A roundup of the hottest topics
HELP
News
- Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric MarketPR Newswire
- Helus Pharma appoints Michael Cola as CEO [Seeking Alpha]Seeking Alpha
- Cybin (NASDAQ:HELP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $22.00 price target on the stock.MarketBeat
- Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq [Yahoo! Finance]Yahoo! Finance
- HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq [Yahoo! Finance]Yahoo! Finance
HELP
Sec Filings
- 2/10/26 - Form 6-K
- 1/12/26 - Form D
- HELP's page on the SEC website